Effect of Different Doses of Budesonide on Markers of Bone Metabolism in Children With Asthma
NCT ID: NCT00487773
Last Updated: 2010-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
96 participants
INTERVENTIONAL
2007-09-30
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma
NCT00490243
Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)
NCT00394355
Short- and Long Term Growth in Children With Asthma
NCT00380484
To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
NCT04848662
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo
NCT01136382
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
budesonide
budesonide
budesonide
2
D3 vitamin
D3 vitamin
D3 vitamin
3
montelukast sodium
montelukast sodium
montelukast sodium
4
salbutamol
salbutamol
salbutamol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
budesonide
budesonide
D3 vitamin
D3 vitamin
montelukast sodium
montelukast sodium
salbutamol
salbutamol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Never treated chronically (longer than at least 3 months) with anti-asthmatic drugs
* Newly-diagnosed or non-treated asthma
* Must be able to inhale drugs
Exclusion Criteria
* Other chronic diseases
* Asthma exacerbation
* Pregnancy
5 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Lodz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Pediatrics and Allergy, Medical University of Lodz, Poland
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Malgorzata Olszowiec-Chlebna, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Pediatrics and Allergy, Medical University of Lodz, Poland
Iwona Stelmach, MD, PhD, Prof
Role: STUDY_CHAIR
Department of Pediatrics and Allergy, Medical University of Lodz, Poland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pediatrics and Allergy, Medical University of Lodz
Lodz, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RNN-87-06-KE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.